losartan has been researched along with Cataract in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shree, J | 1 |
Choudhary, R | 1 |
Bodakhe, SH | 1 |
Pecci, A | 1 |
Granata, A | 1 |
Fiore, CE | 1 |
Balduini, CL | 1 |
2 other studies available for losartan and Cataract
Article | Year |
---|---|
Losartan delays the progression of streptozotocin-induced diabetic cataracts in albino rats.
Topics: Administration, Oral; Administration, Topical; Aldehyde Reductase; Angiotensin II Type 1 Receptor Bl | 2019 |
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2008 |